Aurora Innovation, Inc.

# Signal Note: Eventide Initiates Aurora Innovation Position Eventide's $73K entry into Aurora Innovation (AUROW) signals conviction in the company's pipeline, likely driven by Aurora's lead program in neurodegenerative disease or rare indications where values-aligned investors see unmet need. The modest position size suggests early-stage conviction or a test position ahead of potential clinical readouts or partnering announcements expected in 2024-2025. Monitor for upcoming trial data or licensing deals that could validate the thesis.